# Biotech investors in China (2026 list)

> 46 biotech investors in China, 100% active in the last 12 months. Led by Qiming Venture Partners, IDG Capital, HSG. Ranked by what they funded.

Source: https://millionrounds.com/lists/biotech-investors-in-china (Millionrounds; every figure on the page links to its filing or article)

[Investor Lists](https://millionrounds.com/lists)

# Biotech investors in China

Updated 7 November 2026

Firms observed backing a biotech company in China in the last two years, wherever the firm is based.

[See all 46 *→*](https://millionrounds.com/login?join=1&next=%2Fapp%2Finvestor-lists%2Fbiotech-investors-in-china)The top 25

**46** investors on the list No change this week

**532** cheques in 12 months *+12%* against the market

**$30M** median round they joined *+281%* against the market median

**100%** wrote a cheque in 12 months

**43%** have led a round

## The Top 25

Ordered by cheques observed, never by anything anyone paid for

Deploying now (25)

- 1 [Qiming Venture Partners](https://millionrounds.com/fund/qiming-venture-partners) *Deploying now* VC firm · Hong Kong SAR China **526** **$25M** median round **Oct 2026** last seen
- 2 [IDG Capital](https://millionrounds.com/fund/idg-capital) *Deploying now* Private equity · China **504** **$25M** median round **Oct 2026** last seen
- 3 [HSG](https://millionrounds.com/fund/hsg) *Deploying now* VC firm · Hong Kong SAR China **498** **$31M** median round **Oct 2026** last seen
- 4 [Shenzhen Capital Group Co.](https://millionrounds.com/fund/shenzhen-capital-group) *Deploying now* Government · China **449** **$16M** median round **Oct 2026** last seen
- 5 [OrbiMed](https://millionrounds.com/fund/orbimed) *Deploying now* Private equity · United States **447** **$71M** median round **Oct 2026** last seen
- 6 [Shunwei Capital](https://millionrounds.com/fund/shunwei-capital) *Deploying now* VC firm · China **288** **$15M** median round **Oct 2026** last seen
- 7 [Hill House Capital](https://millionrounds.com/fund/hill-house-capital) *Deploying now* Family office · Singapore **248** **$60M** median round **Sept 2026** last seen
- 8 [Gobi Partners](https://millionrounds.com/fund/gobi-partners) *Deploying now* VC firm · Malaysia **212** **$10M** median round **Oct 2026** last seen
- 9 [Gaorong Capital](https://millionrounds.com/fund/gaorong-capital) *Deploying now* VC firm · China **184** **$30M** median round **Nov 2026** last seen
- 10 [Vivo Capital](https://millionrounds.com/fund/vivo-capital) *Deploying now* Private equity · United States **140** **$64M** median round **Sept 2026** last seen
- 11 [Eli Lilly](https://millionrounds.com/fund/eli-lilly) *Deploying now* Corporate VC · United States **137** **$56M** median round **Nov 2026** last seen
- 12 [5Y Capital](https://millionrounds.com/fund/5y-capital) *Deploying now* VC firm · China **126** **$28M** median round **Oct 2026** last seen
- 13 [Oriza Holdings](https://millionrounds.com/fund/oriza-holdings) *Deploying now* VC firm · China **101** **$14M** median round **Oct 2026** last seen
- 14 [TCG Crossover](https://millionrounds.com/fund/tcg-crossover) *Deploying now* VC firm · United States **60** **$150M** median round **Oct 2026** last seen
- 15 [Boyu Capital](https://millionrounds.com/fund/boyu-capital) *Deploying now* Private equity · Hong Kong SAR China **20** **$260M** median round **Oct 2026** last seen
- 16 [Decheng Capital](https://millionrounds.com/fund/decheng-capital) *Deploying now* VC firm · United States **17** **$35M** median round **Sept 2026** last seen
- 17 [GL Ventures](https://millionrounds.com/fund/gl-ventures) *Deploying now* VC firm **6** **$39M** median round **Nov 2026** last seen
- 18 [Yunmu Capital](https://millionrounds.com/fund/yunmu-capital) *Deploying now* VC firm · China **3** **$30M** median round **Oct 2026** last seen
- 19 [Guofang Venture Capital](https://millionrounds.com/fund/guofang-venture-capital) *Deploying now* VC firm **3** **$200M** median round **Nov 2026** last seen
- 20 [Cenova Capital](https://millionrounds.com/fund/cenova-capital) *Deploying now* Growth equity · China **2** **$75M** median round **May 2026** last seen
- 21 [China Life Capital](https://millionrounds.com/fund/china-life-capital) *Deploying now* VC firm **2** **$1.3B** median round **Oct 2026** last seen
- 22 [Seas Capital](https://millionrounds.com/fund/seas-capital) *Deploying now* VC firm · China **2** **$21M** median round **Mar 2026** last seen
- 23 [LAV](https://millionrounds.com/fund/lav) *Deploying now* Growth equity **2** **$100M** median round **May 2026** last seen
- 24 [Dalton Venture](https://millionrounds.com/fund/dalton-venture) *Deploying now* VC firm · China **1** **$22M** median round **Mar 2026** last seen
- 25 [Liepin](https://millionrounds.com/fund/liepin) *Deploying now* Corporate VC **1** **$22M** median round **Mar 2026** last seen

**21 more on this list**

All 46 are in the app, with filters for stage, sector and market. A free account shows 10 per search, Pro up to 1,000.

[See the whole list *→*](https://millionrounds.com/login?join=1&next=%2Fapp%2Finvestor-lists%2Fbiotech-investors-in-china)

## The Newest Cheques

Rounds this list's investors joined most recently

- **5** Nov **[T-Therapeutics](https://millionrounds.com/company/t-therapeutics)** Series B · $133M *With* [Eli Lilly](https://millionrounds.com/fund/eli-lilly)
- **5** Nov **[Sand.ai](https://millionrounds.com/company/sand-ai)** Series A · $200M *With* [Guofang Venture Capital](https://millionrounds.com/fund/guofang-venture-capital)
- **3** Nov **[Nanochap](https://millionrounds.com/company/nanochap)** Series C · $75M *Led by* [Gaorong Capital](https://millionrounds.com/fund/gaorong-capital)
- **2** Nov **[General Medicine](https://millionrounds.com/company/general-medicine)** Series B · $120M *With* [Eli Lilly](https://millionrounds.com/fund/eli-lilly)
- **2** Nov **[GenRobot AI](https://millionrounds.com/company/genrobot-ai)** Series A · $100M *With* [GL Ventures](https://millionrounds.com/fund/gl-ventures)
- **30** Oct **[Archon Robotics](https://millionrounds.com/company/archon-robotics)** Seed *With* [IDG Capital](https://millionrounds.com/fund/idg-capital)

## Stages This Year

397 rounds

- Venture **27%**
- Other **18%**
- Series B **12%**
- Series A **11%**
- Series C **8%**
- Other **23%**

## What They Backed

Sectors, last 12 months

- Biotech **128**
- AI **97**
- Healthcare **54**
- Pharma **39**
- Robotics **16**
- Hardware & Electronics **14**

## Cheques by Quarter

Led Joined

109 Q1 25

88 Q2 25

174 Q3 25

188 Q4 25

206 Q1 26

110 Q2 26

88 Q3 26

40 Q4 26

The last bar is the quarter still running.

## Lists Like This

- [AI investors in United States 3,683](https://millionrounds.com/lists/ai-investors-in-united-states)
- [Fintech investors in United States 1,166](https://millionrounds.com/lists/fintech-investors-in-united-states)
- [AI investors in United Kingdom 1,039](https://millionrounds.com/lists/ai-investors-in-united-kingdom)
- [Big Data & Analytics investors in United States 1,039](https://millionrounds.com/lists/big-data-investors-in-united-states)
- [Biotech investors in United States 914](https://millionrounds.com/lists/biotech-investors-in-united-states)
- [Energy investors in United States 798](https://millionrounds.com/lists/energy-investors-in-united-states)
- [Robotics investors in United States 797](https://millionrounds.com/lists/robotics-investors-in-united-states)
- [Construction investors in United States 742](https://millionrounds.com/lists/construction-investors-in-united-states)
- [Cybersecurity investors in United States 702](https://millionrounds.com/lists/cybersecurity-investors-in-united-states)

[All investor lists *→*](https://millionrounds.com/lists)

## Reading for founders in health and biotech

- The Innovator's Prescription: A Disruptive Solution for Health Care Clayton M. Christensen · 2008 4.21 from 1,158 ratings on Goodreads Health and biotech Innovation Moats and competition About the book A groundbreaking prescription for health care reform--from a legendary leader in innovation... Our health care system is in critical condition. Each year, fewer Americans can afford it, fewer businesses can provide it, and fewer government programs can promise it for future… On AmazonListen on Audible
- Where Does It Hurt?: An Entrepreneur's Guide to Fixing Health Care Jonathan Bush · 2014 3.78 from 598 ratings on Goodreads Health and biotech Company building Innovation About the book A bold new remedy for the sprawling and wasteful health care industry Where else but the doctor’s office do you have to fill out a form on a clipboard? Have you noticed that hospital bills are almost unintelligible, except for the absurdly high dollar amount? Why is it that… On AmazonListen on Audible
- Ashes to Ashes: America's Hundred-Year Cigarette War, the Public Health, and the Unabashed Triumph of Philip Morris Richard Kluger · 1997 3.94 from 306 ratings on Goodreads Health and biotech Company building About the book Ashes to Ashes is a monumental history of the American tobacco industry’s ironic success in developing the cigarette, modern society’s most widespread instrument of self-destruction, into the nation’s most profitable consumer product. Starting with its energized, work-obsessed… On AmazonListen on Audible
- The Kelloggs: The Battling Brothers of Battle Creek Howard Markel · 2017 3.87 from 969 ratings on Goodreads Health and biotech Company building About the book "What's more American than Corn Flakes?" --Bing Crosby From the much admired medical historian ("Markel shows just how compelling the medical history can be"--Andrea Barrett) and author of An Anatomy of Addiction ("Absorbing, vivid"--Sherwin Nuland, The New York Times Book… On AmazonListen on Audible

More books for founders and investors on the [Reading List](https://millionrounds.com/reading-list?role=founder&industry=health).

As an Amazon Associate we earn from qualifying purchases.

## Quick answers about biotech investors in China

### Who are the most active biotech investors in China?

By cheques observed, the most active are Qiming Venture Partners, IDG Capital, HSG, Shenzhen Capital Group Co. and OrbiMed.

### How many biotech investors in China are there?

46 are on record. 100% made an investment in the last 12 months and 43% have led a round.

### Which stages do biotech investors in China back?

Of the rounds with a named stage in the last 12 months, mostly Series B (24%) and Series A (21%).

### How big are the rounds biotech investors in China join?

The typical (median) round among the leading investors here is $31M.

### Which sectors do biotech investors in China back most?

In the last 12 months, mostly Biotech, AI and Healthcare.

### Which biotech investors in China lead the most rounds?

OrbiMed (9 led), Qiming Venture Partners (8 led) and IDG Capital (8 led).

### Where are biotech investors in China based?

Among the most active, most are based in China (10), the United States (5) and Hong Kong SAR China (3).

### What have biotech investors in China invested in recently?

Recent rounds include T-Therapeutics (Series B, Nov 2026, with Eli Lilly), Sand.ai (Series A, Nov 2026, with Guofang Venture Capital) and Nanochap (Series C, Nov 2026, with Gaorong Capital).

Built from the rounds we watched, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections)